No Need for Open-Chest Surgery: Stem Cell Patch Enables Minimally Invasive Heart Repair
Release time:
2025-12-12
Recently, a joint research team from the Mayo Clinic and the University of Nebraska Medical Center published a breakthrough study in the Journal of Biomedical Materials Research—they successfully developed a minimally implantable stem cell patch that can repair damaged hearts without open-chest surgery, providing a safer treatment option for heart failure patients. This achievement signifies the deep integration of regenerative medicine and minimally invasive interventional technology, which is expected to reshape the clinical approach to heart repair.
Heart failure is one of the leading causes of death worldwide. Among traditional treatment methods, in addition to medication control, severely ill patients often rely on mechanical pump assistance or even heart transplantation. However, the former carries a high risk of complications, while the latter faces a scarcity of donors. Previously, scientists attempted to replace damaged tissue with stem cell-derived cardiomyocytes, but the need for open-chest surgery deterred most patients. Even when using induced pluripotent stem cells (iPSCs) reprogrammed from skin or blood cells and cultured into cardiomyocytes, the safe and efficient delivery of these cells remained a critical bottleneck.
To address this challenge, the research team adopted an interdisciplinary engineering and biological perspective to design a flexible, ultra-thin stem cell patch. Its core consists of a nano-microfiber hybrid scaffold coated with gelatin as a substrate, which can carry reprogrammed and cultured human cardiomyocytes, vascular cells, and fibroblasts, forming a living, autonomously beating heart-like tissue. Before transplantation, the patch is infused with bioactive components such as fibroblast growth factor to promote angiogenesis and enhance cell survival.
More ingeniously, the patch can be folded like paper and precisely delivered to the target area of the heart through a small chest incision via a thin catheter. Once in place, it automatically unfolds and tightly adheres to the heart wall. Fixed with a biocompatible surgical adhesive, it avoids damage to surrounding tissues while ensuring stable anchoring. Preclinical trials showed that, compared to traditional methods, this minimally invasive implantation significantly improved heart function, reduced scar formation, promoted blood vessel growth, and simultaneously alleviated inflammation while activating the heart’s self-repair capabilities.
The breakthrough of this technology lies not only in avoiding high-risk open-chest surgery but also in the clever integration of regenerative medicine with minimally invasive interventions, overcoming the delivery barrier of stem cell therapy. The team emphasized that patients with severe heart failure currently have limited treatment options, and the patch solution offers a safer alternative for this population.
If this technology can be applied on a large scale in the future, it may significantly reduce hospitalization rates and medical burdens for heart failure patients, impacting the global landscape of cardiovascular health. In the long term, it could provide a replicable template for regenerative therapies for other organs, accelerating the translation of regenerative medicine into clinical practice. From "open-chest heart replacement" to "patch-based heart repair," this quiet medical revolution is sustaining life in a gentler way.
Latest developments
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
The significance of life extension lies not only in technological breakthroughs but also in the shared belief of every individual who believes in "a better future." With faith as their torch, these fellow travelers join hands, pooling their strength to stride forward together. We firmly believe that as this steadfast support converges into a powerful force, it will propel the Yinfeng Life Extension Plan to gain broader attention, inject continuous momentum into the development of cryobiomedicine, and illuminate the next chapter of human civilization.
Over the two days, the symposium was not only a collision of ideas but also seeds sown to advance social progress in life culture. The Shandong Yinfeng Life Science Public Welfare Foundation will continue to use technology as wings and culture as roots, collaborating with all sectors of society to enhance the quality of life for the Chinese people and build a human-centered life care system.
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
